Inclusion Criteria:

          -  Women >= 18 years.

          -  Ductal carcinoma in situ (DCIS) that express HER-2 3+ on 10% of the DCIS that have not
             had definitive surgery are diagnosed by core biopsy or NL surgical biopsy with
             positive margins.

          -  Patients that are ER+ will take anti-estrogen therapy for treatment of their DCIS
             during vaccinations.

          -  Women of childbearing age with a negative pregnancy test documented prior to
             enrollment.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1.

          -  Women of childbearing potential must agree to use a medically acceptable form of birth
             control during their participation in the study.

          -  Have voluntarily signed a written Informed Consent in accordance with institutional
             policies after its contents have been fully explained to them.

        Exclusion Criteria

          -  Pregnant or lactating.

          -  Positive for HIV or hepatitis C at baseline by self-report.

          -  Potential participants with coagulopathies, including thrombocytopenia with platelet
             count <75,000, INR> 1.5 and partial thromboplastin time > 50 sec

          -  Major cardiac illness MUGA or ECHO <50% EF.

          -  Pre-existing medical illnesses or medications which might interfere with the study as
             determined by Principal Investigator (PI).